Rapid Readouts: Results of Phase 3 DREAMseq Trial in Advanced Melanoma
Source: OncLive, February 2022
Michael Atkins, MD, shares data presented at the 2021 American Society of Clinical Oncology Plenary Series regarding results from the phase 3 ECOG-ACRIN EA6134 trial, DREAMseq, evaluating the use of up-front dual immunotherapy in patients with BRAF V600–mutant advanced melanoma.
Michael B. Atkins, MD,discusses data from the following poster: “DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): a phase III trial—ECOG-ACRIN EA6134.” (Atkins MB, et al. ASCO 2021 Plenary Series, Abstract 356154).
- Combinations of immune checkpoint inhibitors blocking PD-1 and CTLA4 or BRAF/MEK inhibitors have shown significant antitumor efficacy and overall survival (OS) benefit in patients with BRAF V600–mutant metastatic melanoma, leading to broad regulatory approval.
- The objective of this presentation was to provide the results of the phase 3, DREAMseq trial, designed to compare the efficacy and toxicity of nivolumab-ipilimumab followed by dabrafenib-trametinib with the converse sequence.